Contribute Try STAT+ Today

More than two dozen state attorneys general are objecting to part of a possible deal between the federal government and Purdue Pharma that would resolve alleged criminal and civil charges over the company’s role in fueling the opioid crisis.

Specifically, the state officials are upset that the drug maker would be transformed into a public benefit company and run on behalf of the numerous communities around the U.S. that have been pursuing Purdue for compensation. A report earlier this month by Reuters indicated the Department of Justice is considering such a move as part of a broader settlement that could be announced as soon as this month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy